PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1477257
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1477257
Gastric Motility Disorder Drug Market, By Disorder Type, By Drug Class, By Distribution Channel, By Geography
The gastric motility disorder drug market is estimated to be valued at USD 57.65 Bn in 2024 and is expected to reach USD 83.15 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 57.65 Bn |
| Historical Data for: | 2019 To 2023 | Forecast Period: | 2024 To 2031 |
| Forecast Period 2024 to 2031 CAGR: | 5.40% | 2031 Value Projection: | US$ 83.15 Bn |
Gastric motility disorder refers to conditions wherein the stomach takes more or less time than usual to empty its contents. Some common gastric motility disorders include gastroparesis and functional dyspepsia. Gastroparesis occurs when the muscle movements in the stomach are either sluggish or disordered, causing food to get stuck in the stomach for a longer duration than normal. It affects the normal digestive process and often causes nausea, bloating, and vomiting. Similarly, functional dyspepsia involves impaired gastric emptying processes leading to discomfort in the upper abdomen. The exact causes of gastric motility disorders are unknown in many cases; however, they may arise due to damage to the vagus nerve, diabetes, certain medications, surgery, or other underlying health conditions. Currently available drug therapies for gastric motility disorders include prokinetics that aim to stimulate gastric motility and hasten gastric emptying. Given the chronic nature and lack of complete cure for such disorders, the global gastric motility drug market is poised to grow steadily in the coming years.
Market Dynamics:
The global gastric motility drug market is driven by the increasing prevalence of diabetes as it is a high-risk factor for gastroparesis. Extended hospital stays and loss of work productivity associated with gastric motility disorders also contribute to their growing economic burden. This is anticipated to fuel the demand for more effective drug therapies. However, the market potential is restricted by the lack of approved drugs for some types of gastric motility disorders. Moreover, side effects associated with existing drug options pose a major challenge. Development of novel drug formulations with better safety profiles can present lucrative opportunities in this market. Adoption of combination therapies and development of region-specific formulations tailored to address the unmet needs are some key opportunities.
Key Features of the Study:
- This report provides an in-depth analysis of the global gastric motility disorder drug market, and provides market size (USD BN) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global gastric motility disorder drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study includes Pfizer Inc., Takeda Pharmaceutical Company Limited, Janssen Pharmaceuticals, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Boehringer Ingelheim, Eli Lilly and Company, Bristol Myers Squibb, Daiichi Sankyo Company, Limited, Bausch Health Companies, Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals, Eisai Co., Ltd., Ferring Pharmaceuticals, UCB, Evoke Pharma, and Cadila Pharmaceuticals.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global gastric motility disorder drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global gastric motility disorder drug market.
Detailed Segmentation-
- Disorder Type:
- Upper Digestive Tract
- Achalasia
- Gastroesophageal Reflux Disease (GERD)
- Gastroparesis
- Dumping Syndrome
- Lower Digestive Tract
- Intestinal Pseudo-obstruction
- Small Intestinal Bacterial Overgrowth (SIBO)
- Pelvic Dyssynergia
- Hirschsprung's Disease
- Drug Class:
- Antacids
- Antidiarrheals
- Calcium-channel Blockers
- H2 Blockers
- Proton Pump Inhibitors
- Others
- Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Pfizer Inc.
- Takeda Pharmaceutical Company Limited
- Janssen Pharmaceuticals
- Sun Pharmaceutical Industries Ltd.
- AbbVie Inc.
- Boehringer Ingelheim
- Eli Lilly and Company
- Bristol Myers Squibb
- Daiichi Sankyo Company, Limited
- Bausch Health Companies
- Mallinckrodt Pharmaceuticals
- Endo Pharmaceuticals
- Eisai Co., Ltd.
- Ferring Pharmaceuticals
- UCB
- Evoke Pharma
- Cadila Pharmaceuticals
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Disorder Type
- Market Snapshot, By Drug Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Recent Developments
- Acquisitions and Partnerships Scenario
- Technology Overview
- Regulatory Scenario
- Pricing Analysis
- PEST Analysis
4. Global Gastric Motility Disorder Drug Market - Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 impact on the market
5. Global Gastric Motility Disorder Drug Market, By Disorder Type, 2019 - 2031, (USD BN)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Upper Digestive Tract
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Achalasia
- Gastroesophageal Reflux Disease (GERD)
- Gastroparesis
- Dumping Syndrome
- Lower Digestive Tract
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Intestinal Pseudo-obstruction
- Small Intestinal Bacterial Overgrowth (SIBO)
- Pelvic Dyssynergia
- Hirschsprung's Disease
6. Global Gastric Motility Disorder Drug Market, By Drug Class, 2019 - 2031, (USD BN)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Antacids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Antidiarrheals
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Calcium-channel Blockers
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- H2 Blockers
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Proton Pump Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
7. Global Gastric Motility Disorder Drug Market, By Distribution Channel, 2019 - 2031, (USD BN)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
8. Global Gastric Motility Disorder Drug Market, By Region, 2019 - 2031, (USD BN)
- Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2019-2031
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disorder Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disorder Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disorder Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disorder Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disorder Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disorder Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD BN)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Takeda Pharmaceutical Company Limited
- Janssen Pharmaceuticals
- Sun Pharmaceutical Industries Ltd.
- AbbVie Inc.
- Boehringer Ingelheim
- Eli Lilly and Company
- Bristol Myers Squibb
- Daiichi Sankyo Company, Limited
- Bausch Health Companies
- Mallinckrodt Pharmaceuticals
- Endo Pharmaceuticals
- Eisai Co., Ltd.
- Ferring Pharmaceuticals
- UCB
- Evoke Pharma
- Cadila Pharmaceuticals
10. Analyst View
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact
